The MS Choices Survey: Findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 629-643

  Riñon, Alberto ^a,b   Buch, Mandy ^c   Holley, Derek ^c   Verdun, Elisabetta ^a,b  

^a MERCK SERONO S A   (Switzerland)

^b MERCK KGAA   (Germany)

^c GfK HealthCare   (United Kingdom)

Author keywords

Adherence; Management; Multiple sclerosis; Patient attitudes; Treatment initiation

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DOCTOR PATIENT RELATION; HEALTH CARE SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PHYSICIAN ATTITUDE; QUESTIONNAIRE; TREATMENT PLANNING; TREATMENT REFUSAL; TREATMENT RESPONSE;

EID: 84866512508     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S26479     Document Type: Article

References (21)

1. Bennett JL, Stuve O. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications. Clin Neuropharmacol. 2009;32:121-132.
2. McDonald WI. Relapse, remission, and progression in multiple sclerosis. N Engl J Med. 2000;343:1486-1487.
3. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ. 2006;332:525-527.
4. Compston A, Confavreux C, Lassmann H. McAlpine's Multiple Sclerosis. 4th ed. Philadelphia, PA: Churchill Livingstone; 2006.
5. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343: 1430-1438.
6. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain. 1989;112(Pt 1):133-146.
7. World Health Organization. Adherence to long-term therapies: evidence for action. Available from: http://www.who.int/chp/knowledge/publications/ adherence_report/en/index.html. Accessed August 21, 2011.
8. Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin Drug Deliv. 2009;6:995-1002.
9. Treadaway K, Cutter G, Salter A, et al. Factors that influence adherence with disease-modifying therapy in MS. J Neurol. 2009;256:568-576.
10. Halpern R, Agarwal S, Dembek C, Borton L, Lopez-Bresnahan M. Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis. Patient Prefer Adherence. 2011;5:73-84.
11. Tan H, Cai Q, Agarwal S, Stephenson JJ, Kamat S. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis. Adv Ther. 2011;28:51-61.
12. Al-Sabbagh A, Bennet R, Kozma C, Meletiche D. Medication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care database. J Neurol. 2008;255(Suppl 2):S79.
13. Uitdehaag B, Constantinescu C, Cornelisse P, et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study. Ther Adv Neurol Disord. 2011;4:3-14.
14. Tremlett HL, Oger J. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology. 2003;61:551-554.
15. O'Rourke KE, Hutchinson M. Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler. 2005;11:46-50.
16. Multiple Sclerosis International Federation. Atlas of MS Database 2007. Available from: http://www.atlasofms.org/query.aspx?pqyyes&sy1&q1 3&r3Global&yearG2007. Accessed August 21, 2011.
17. Tremlett H, Vander Mei I, Pittas F, et al. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses. Pharmacoepidemiol Drug Saf. 2008;17:565-576.
18. Multiple Sclerosis International Federation. MS: the Guide to Treatment and Management 2008. Available from: http://www.msif.org/ en/resources/msif_resources/msif_publications/ms_the_guide_to_treatment_ and_management/treatments_affecting_longterm_course_ of_disease/index.html. Accessed August 21, 2011.
19. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol. 2008;59:131-135.
20. Ri J, Porcel J, Tellez N, et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult Scler. 2005;11:306-309.
21. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353:487-497.